Venture Life Group (LON:VLG) Shares Cross Above 50 Day Moving Average - What's Next?

Key Points

• Venture Life Group's stock price recently surpassed its 50-day moving average of GBX 59.18, currently trading at GBX 59.70.
• The company reported a quarterly earnings per share (EPS) of GBX 3.96 and a forecasted EPS of 6.14 for the current year.
• Insider Jerry Randall purchased 50,000 shares at an average cost of GBX 59 per share, indicating potential confidence in the company's stock.

Shares of Venture Life Group plc (LON:VLG - Get Free Report) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 59.18 ($0.80) and traded as high as GBX 59.90 ($0.81). Venture Life Group shares last traded at GBX 59.70 ($0.81), with a volume of 31,523 shares.

Venture Life Group Price Performance

The business's 50 day moving average price is GBX 59.17 and its 200 day moving average price is GBX 50.38. The stock has a market capitalization of £74.79 million, a P/E ratio of -23,360.00, a price-to-earnings-growth ratio of 5.67 and a beta of 0.30. The company has a debt-to-equity ratio of 28.45, a current ratio of 2.22 and a quick ratio of 1.48.

Venture Life Group (LON:VLG - Get Free Report) last announced its quarterly earnings results on Monday, June 30th. The company reported GBX 3.96 EPS for the quarter. Venture Life Group had a net margin of 1.44% and a return on equity of 0.99%. Sell-side analysts forecast that Venture Life Group plc will post 6.1391542 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jerry Randall purchased 50,000 shares of the stock in a transaction on Wednesday, July 2nd. The shares were acquired at an average price of GBX 59 per share, with a total value of £29,500. 6.77% of the stock is owned by corporate insiders.

About Venture Life Group

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples.